- Hepatokines as a Link between Obesity and Cardiovascular Diseases
-
Yoo HJ, Choi KM
- KMID: 2280651
- Diabetes Metab J.
- 2015 Feb;39(1):10-15.
- doi: 10.4093/dmj.2015.39.1.10
Non-alcoholic fatty liver disease, which is considered a hepatic manifestation of metabolic syndrome, independently increases the risks of developing cardiovascular disease (CVD) and type 2 diabetes mellitus. Recent emerging evidence... -
- CITED
-
- Close
- SHARE
-
- Close
- Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease
-
Choi HY, Hwang SY, Lee CH, Hong HC, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM
- KMID: 2280744
- Diabetes Metab J.
- 2013 Feb;37(1):63-71.
- doi: 10.4093/dmj.2013.37.1.63
BACKGROUND: Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP,... -
- CITED
-
- Close
- SHARE
-
- Close
- Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK
-
Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY
- KMID: 2282008
- Endocrinol Metab.
- 2015 Jun;30(2):177-184.
- doi: 10.3803/EnM.2015.30.2.177
BACKGROUND: Selenoprotein P (SEPP1) and fetuin-A, both circulating liver-derived glycoproteins, are novel biomarkers for insulin resistance and nonalcoholic fatty liver disease. However, the effect of exendin-4 (Ex-4), a glucagon-like peptide-1... -
- CITED
-
- Close
- SHARE
-
- Close
